Study of HSK31858 tablets for lung mucus conditions
Treatments studied
Part of Lungs & breathing clinical trials.
This trial tests an investigational tablet for people with chronic lung diseases like bronchiectasis, COPD, or asthma who produce at least 10 mL of sputum (mucus coughed up from the lungs) each day. The goal is to see if the drug safely reduces excess airway mucus.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have a chronic lung condition such as bronchiectasis, COPD, or asthma.
- You produce at least 10 mL of sputum (phlegm) in a 24-hour period.
- You are not currently having an asthma flare-up or lung infection needing treatment.
- You have not had significant coughing up of blood (more than a small amount) in the past 4 weeks.
- You agree to use effective contraception if you or your partner could become pregnant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an experimental tablet called XH-S004 for people with moderate-to-severe COPD. It looks at how safe the drug is, how the body processes it, and if it helps symptoms.
This trial tests if a new drug, GSK3862995B, is safe and effective for adults with bronchiectasis. It might help reduce lung infections and improve symptoms.
This study is looking at how mucus builds up in the airways of people with asthma, COPD, or chronic cough. Researchers will also compare findings to healthy volunteers. The goal is to better understand these conditions and find new ways to help.
This trial tests an inhaled medication for people with bronchiectasis, a lung condition causing chronic cough and mucus. It first checks safety in healthy volunteers, then studies how the drug works in people with bronchiectasis.
This trial tests a new inhaled drug, HSK39004, to see if it safely improves breathing and quality of life in people with moderate to severe COPD. You may join if you are between 40 and 80, have a COPD diagnosis with certain lung function results, and have at least some shortness of breath with daily activities.
This trial tests a new medicine, Hemay005, in adults with moderate to severe COPD who also have a chronic cough with mucus. It looks at how the drug affects certain markers in the body related to the disease.
Hear when a new Asthma Bronchiale trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.